Santhanam Lakshminarayanan
Overview
Explore the profile of Santhanam Lakshminarayanan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
542
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kuchipudi N, Kishore S, Kuo C, Lakshminarayanan S, Mandhadi R
Rheumatol Int
. 2021 May;
41(11):1965-1970.
PMID: 34032895
Objective: Our aim was to evaluate the relationship between esophageal dysmotility and lung disease by correlating the results of Echocardiogram and Pulmonary Function Test (PFT) with Esophageal Transit Study (ETT)....
2.
Nehar-Belaid D, Hong S, Marches R, Chen G, Bolisetty M, Baisch J, et al.
Nat Immunol
. 2020 Aug;
21(9):1094-1106.
PMID: 32747814
Patients with systemic lupus erythematosus (SLE) display a complex blood transcriptome whose cellular origin is poorly resolved. Using single-cell RNA sequencing, we profiled ~276,000 peripheral blood mononuclear cells from 33...
3.
Moskalik A, Graber M, Lakshminarayanan S, Bulsara K
World Neurosurg
. 2020 Apr;
139:253-259.
PMID: 32305608
Background: Sarcoidosis is a granulomatous disease most often affecting the lungs, but extrapulmonary manifestations are also common. While virtually any organ system can be involved, skeletal manifestations are present in...
4.
Chandra T, Tabanor-Gayle J, Lakshminarayanan S
Cureus
. 2019 Nov;
11(9):e5598.
PMID: 31700711
Tumor necrosis factor (TNF) inhibitors are used for treatment of different autoimmune diseases. Interestingly they are also being noted to cause autoimmune side effects such as vasculitis, systemic lupus erythematosus,...
5.
Tabanor J, Lakshminarayanan S
Cleve Clin J Med
. 2019 Jul;
86(7):449-453.
PMID: 31291178
No abstract available.
6.
Gkrouzman E, Chirch L, Lakshminarayanan S
J Clin Rheumatol
. 2018 Mar;
25(7):e122-e126.
PMID: 29538086
No abstract available.
7.
Arnold M, Khanna D, Denton C, van Laar J, Frech T, Anderson M, et al.
Rheumatology (Oxford)
. 2017 Oct;
57(1):152-157.
PMID: 29077900
Objectives: Patient acceptable symptom state (PASS) as an absolute state of well-being has shown promise as an outcome measure in many rheumatologic conditions. We aimed to assess whether PASS may...
8.
Khanna D, Denton C, Lin C, van Laar J, Frech T, Anderson M, et al.
Ann Rheum Dis
. 2017 Oct;
77(2):212-220.
PMID: 29066464
Objectives: Assess the efficacy and safety of tocilizumab in patients with systemic sclerosis (SSc) in a phase II study. Methods: Patients with SSc were treated for 48 weeks in an...
9.
Khanna D, Denton C, Jahreis A, van Laar J, Frech T, Anderson M, et al.
Lancet
. 2016 May;
387(10038):2630-2640.
PMID: 27156934
Background: Systemic sclerosis is a rare disabling autoimmune disease with few treatment options. The efficacy and safety of tocilizumab, an interleukin 6 receptor-α inhibitor, was assessed in the faSScinate phase...
10.
Kumar V, Rodner C, Lakshminarayanan S
J Rheumatol
. 2015 Aug;
42(8):1530-1.
PMID: 26233952
No abstract available.